Oncternal Therapeutics, Inc. 10-K Cybersecurity GRC - 2024-03-07

Page last updated on July 16, 2024

Oncternal Therapeutics, Inc. reported their cybersecurity risk management and governance process in a yearly 10-K filed on 2024-03-07 16:20:32 EST.

Filings

10-K filed on 2024-03-07

Oncternal Therapeutics, Inc. filed a 10-K at 2024-03-07 16:20:32 EST
Accession Number: 0000950170-24-027984

Note: filing items unformatted. Drop us a note with the above URL to help us prioritize formatting it!

Item 1C. Cybersecurity.

Item 1C. Cybersecurity . Cybersecurity Risk Management and Strategy We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. Our cybersecurity risk management program includes a cybersecurity incident response plan. Our cybersecurity risk management program includes: - a security team principally responsible for managing our security controls and our response to cybersecurity incidents; - the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls; - cybersecurity awareness training of our employees, incident response personnel, and senior management; and - a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents. We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. For more information, see the section titled “Risk Factor-Risks Related to Our Business Operations and Industry-Our information technology systems, or those of any of our CROs, manufacturers, other contractors or consultants or potential future collaborators, may fail or suffer cyberattacks or other security breaches, which could have a material adverse effect on our business, results of operation, and financial condition, and result in a material disruption of our product development programs.” Cybersecurity Governance Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee (“Committee”) oversight of cybersecurity and other information technology risks. The Committee oversees management’s implementation of our cybersecurity risk management program. The Committee receives periodic reports from management on our cybersecurity risks. In addition, management updates the Committee, as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential. The Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also receives briefings from management on our cyber risk management program. Board members receive presentations on cybersecurity topics from our Head of IT or external experts as part of the Board’s continuing education on topics that impact public companies. Our management team, including our Chief Executive Officer, General Counsel, and Head of IT, is responsible for assessing and managing our material risks from cybersecurity threats. The team has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel. Our management team’s experience includes a Head of IT with over 30 years’ experience leading the IT and cybersecurity functions for companies similar to ours. Our management team supervises efforts to identify, protect, detect, respond and recover cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information 80 obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in the IT environment. 81


Company Information

NameOncternal Therapeutics, Inc.
CIK0001260990
SIC DescriptionPharmaceutical Preparations
TickerONCT - Nasdaq
Website
CategoryNon-accelerated filer
Smaller reporting company
Fiscal Year EndDecember 30